subjects by an indirect mechanism that has not been fully elucidated.
jects attended the laboratory for a screening solutions of doubling concentrations from 0.25 to 32 mg/ml. Solutions were administered by visit and two study visits, with a washout period of at least 48 hours between each attendance. tidal breathing for one minute via a Ventstream nebuliser driven by medical air at 8 l/min. Each subject completed the study within four weeks of screening. Subjects abstained from Spirometric values were measured at baseline, three minutes after inhalation of saline, and short acting bronchodilators for at least eight hours and from long acting bronchodilators three minutes after inhalation of each dose of propranolol. Doses were given at five minute and cromones for at least 12 hours prior to each visit. Inhaled corticosteroids were continued intervals. Challenges were terminated when a 20% or greater fall in FEV 1 from the post saline unchanged throughout the study period.
At screening a medical history was taken and value had been achieved or when the highest concentration of propranolol had been given. a physical examination performed. Subjects then underwent propranolol challenge, and If there was a fall in FEV 1 of more than 15% but less than 20%, spirometric measurements were included in the study if they had a provocative concentration of propranolol causing were repeated after a further five minutes. The next concentration of propranolol was then a 20% fall in FEV 1 (PC 20 FEV 1 propranolol) of Ζ32 mg/ml. Baseline FEV 1 at each study visit administered only if FEV 1 remained above 80% of baseline. The provocative concentration of was required to be [65% predicted and to not deviate by >10% from the screening value. If propranolol causing a 20% reduction in FEV 1 (PC 20 FEV 1 propranolol) was determined by these criteria were not met an appointment was made for reattendance on another day.
linear interpolation from the log concentrationresponse curve. 31 Residual bronchoconstriction On each study day baseline FEV 1 was measured. Subjects then received study drug (fru-was reversed by nebulised salbutamol 2.5 mg plus ipratropium bromide 500 g. Subjects semide 40 mg or placebo) by nebuliser. Five minutes after nebulisation FEV 1 was measured were allowed to leave the laboratory when their FEV 1 had returned to at least 90% of baseline. and each subject's individually predetermined PC 20 FEV 1 propranolol was then administered.
On the two study drug days an abbreviated propranolol challenge was performed with each FEV 1 was recorded at five minute intervals for 15 minutes. Salbutamol 2.5 mg was then subject receiving their individual PC 20 FEV 1 propranolol as a single dose. Salbutamol administered by nebuliser and FEV 1 measured at five minute intervals for 30 minutes or until alone was used to reverse residual bronchoconstriction. baseline FEV 1 was regained.
,     
Results are expressed as mean (SD) using the   Spirometric measurements were made using value before frusemide/placebo administration as the baseline. Summary measures chara dry wedge bellows spirometer (Vitalograph, Vitalograph Ltd, Buckingham, UK) performed acterising the response to propranolol inhalation (maximum fall in FEV 1 as % baseline and according to American Thoracic Society guidelines. 29 area under the curve of fall in FEV 1 against time) and the rate of recovery following salStudy medication (Lasix for injection supplied by Hoechst Ltd, Hounslow, UK or butamol administration (time to achieve 95% of baseline FEV 1 ) were compared for the active placebo) was delivered via jet nebuliser (Ventstream, Medic-Aid, Sussex, UK) driven by and placebo treatment days using the Wilcoxon signed rank test.
32
Period and carryover medical air at a flow rate of 8 l/min with an output of 0.67 g/min. 30 effects were examined according to standard methods. 33 Propranolol challenge was performed according to a standardised technique modified from that previously described. 4 Anhydrous propranolol hydrochloride powder (Zeneca, Results
Propranolol challenge was generally well tol-UK) was dissolved in normal saline on the day of each study visit and diluted to provide erated although four subjects reported per- propranolol administration and was therefore given ipratropium bromide and salbutamol immediately. No specific distinguishing clinical features were identified to account for this subject's idiosyncratic response. In the other 11 subjects FEV 1 was followed for a full 15 minutes before bronchodilator treatment with maximum bronchoconstriction by five minutes and a further three by 10 minutes, while the remainder showed increased bronchoconstriction at the 15 minute time point. sistent mild wheeze, dry cough and/or increased requirement for inhaled 2 agonist lasting for
The area under the curve of decrease in FEV 1 against time was less after frusemide than up to 12 hours following full propranolol doseresponse assessment. One subject developed placebo (fig 2) but did not reach statistical significance (p=0.051, Wilcoxon), excluding marked bronchoconstriction on the placebo day with a 58% fall in FEV 1 five minutes subject 11 from the analysis. The mean (SD) maximum fall in FEV 1 following propranolol, after propranolol inhalation. She was therefore immediately given nebulised salbutamol and expressed as % baseline, was 18.2 (13.8)% on the placebo day compared with 11.8 (9.4)% ipratropium. This subject's recovery data are not included in the statistical analysis. There following frusemide (fig 1) . This difference was significant (p=0.02), indicating that frusemide were no other adverse events reported after inhalation of single doses of propranolol. All has a bronchoprotective effect against propranolol-induced bronchoconstriction. The subjects achieved at least 95% of baseline FEV 1 within the monitored recovery period following median difference in maximum % fall in FEV 1 within individuals between study days was salbutamol administration.
Baseline FEV 1 did not differ significantly 3.6% (95% CI 1.2 to 11.7). Once again there was considerable individual between the study days: mean (SD) 3.49 (0.81) l on the placebo day and 3.54 (0.87) l on the variation in the degree of bronchoprotection.
One subject showed more than 80% protection frusemide day. Neither frusemide nor saline administration significantly affected FEV 1 : but three subjects had no apparent bronchoprotection at all. These differences showed mean (SD) FEV 1 after saline 3.49 (0.79) l, after frusemide 3.55 (0.89) l.
no apparent relationship to differences between subjects' age, sex, atopic or smoking status, or Administration of the individually determined PC 20 FEV 1 at the placebo study visit baseline PC 20 FEV 1 propranolol.
Data for the recovery period were analysed resulted in a mean (SD) maximum percentage fall in FEV 1 from baseline of 18.2 (13.8)% (fig for 11 subjects. The mean (SD) time taken for FEV 1 to return to at least 95% of baseline was 1). This was not significantly different from the predicted 20% fall, despite the fact that the 9 (10) minutes following frusemide which was not significantly different from 15 (11) minutes dose administered was only half the cumulative dose given during the full dose response. There after placebo.
No period effect on the maximum percentage was, however, considerable individual variation in the extent of bronchoconstriction resulting change in FEV 1 was identified. from this single dose of propranolol -less than 10% in three subjects and more than 30% in one -though all subjects had previously shown Discussion
We have shown that pretreatment with nebufalls in FEV 1 of more than 20% at the screening visit. The maximum fall in FEV 1 following lised frusemide attenuates the bronchoconstrictor response to inhaled propranolol in propranolol inhalation exceeded 20% in three subjects.
mild asthmatic subjects. This observation has not been previously reported. The degree of The early time course of propranololinduced bronchoconstriction varied between bronchoprotection afforded was approximately one third of the unattenuated propranololindividuals. One subject (no. 11, table 1) showed a 58% fall in FEV 1 five minutes after induced fall in FEV 1 , though there was group.bmj.com on April 8, 2017 -Published by http://thorax.bmj.com/ Downloaded from considerable variation between individuals. subjects to the constrictor effect of acetylcholine. 38 39 Frusemide, like sodium cromoglycate, 8 thus provides partial bronchoprotection against proInvolvement of non-adrenergic non-cholinergic (NANC) nerves is suggested by the ability pranolol-induced bronchoconstriction but fails to match the complete protection afforded by of vasoactive intestinal peptide to attenuate propranolol-induced bronchoconstriction. This oxitropium. 4 Inhalation of propranolol causes dose de-effect is additive to that of ipratropium, suggesting that it is not mediated by cholinergic pendent bronchoconstriction in asthmatic subjects which is well tolerated. This study did not nerves. 6 Finally, the cromones sodium cromoglycate and nedocromil sodium have been address the repeatability of the bronchoconstrictor effect of propranolol, which is shown to attenuate propranolol-induced bronchoconstriction. It is likely that they are acting known to be moderate or good. 2 4 7 Interindividual variation in propranolol response on airway nerves though the evidence regarding involvement of mast cells in propranololwas seen, as mentioned above. Nevertheless, the randomised, crossover, placebo controlled induced bronchoconstriction is conflicting.
40-42
Thus, propranolol-induced bronchoconstricdesign should take this into account. As in previous studies, 4 protection against a single tion is likely to be mediated by a number of mechanisms, with airway nerves playing a dose of propranolol was examined rather than constructing a full dose-response curve on each prominent role. This may explain the wide interindividual variation in response to occasion, for convenience and simplicity.
The mechanism of propranolol-induced blockade of propranolol-induced bronchoconstriction by frusemide and other agents. bronchoconstriction is unclear but it is distinct from that of agents that act directly on airway A wide variety of indirectly acting bronchoconstrictor stimuli are antagonised by frusmooth muscle such as methacholine, as shown by the lack of correlation of sensitivity to the semide. [9] [10] [11] [12] [13] [14] [15] The exact mechanism of action by which frusemide exerts these effects remains different agents within individuals and differences in the shapes of the dose-response unclear. It has been postulated to act upon chloride channels in the bronchial epithelium curves.
2 Bronchoconstrictor activity is specific to the -isomer of propranolol, suggesting that but the target cell of such an action has not been established. Alternative hypotheses inthis effect is due to its activity as a 2 adrenoreceptor antagonist, 3 and this is supported clude inhibition of activation of airway inflammatory cells and modulation of cholinergic by the lesser bronchoconstrictor effects of more 1 selective agents 34 and its antagonism by 2 and/or NANC nerves, possibly acting through the enhanced production of bronchoprotective agonists. 4 Human bronchial smooth muscle does not receive significant innervation from prostanoids. 43 The results of the current study do not elucidate this further. sympathetic autonomic nerves, suggesting that circulating catecholamines provide a tonic As with frusemide, the mechanism by which sodium cromoglycate exerts its bronchobronchodilator stimulus and that propranololinduced bronchoconstriction results from its protective effects has not been fully established.
Its ability to inhibit mediator release from mast blockade. 35 This is supported by a report of bronchoconstriction following inhalation of cells has been demonstrated, 44 but it can also block activation of bronchial C fibres, 45 antpropranolol in one heart-lung transplant recipient. 36 However, this may not be the full agonise the actions of platelet activating factor, 46 and inhibit protein kinase C activity, 47 explanation of propranolol-induced bronchoconstriction in asthma, in view of the wide all of which could be relevant to its ability to attenuate indirectly provoked bronchoconvariety of inhaled agents that antagonise it and the very low background levels of circulating striction.
Our findings are consistent with the known catecholamines in the plasma of resting subjects. 3 properties of the agents studied and with the hypothesis that frusemide and the cromones Sympathetic nerves have been described within autonomic ganglia in the lungs and in provide bronchoprotection against indirect challenge by similar mechanisms. The interclose proximity to cholinergic nerves. 35 There is strong evidence for a role of the para-subject variability is consistent with multiple mechanisms of both propranolol-induced sympathetic nervous system in propranololinduced bronchoconstriction with blockade by bronchoconstriction and frusemide bronchoprotection and is also seen with cromones. atropine, 37 oxitropium bromide, 4 and by presynaptic agonists such as pilocarpine. 5 In guinea Our observations do not provide any further insight into the mechanisms of action of the pigs ganglionic blockade with hexamethonium blocks propranolol-induced bronchoconstric-agents discussed, neither do they suggest a therapeutic role for frusemide in the treatment tion. Beta agonists have been shown to inhibit acetylcholine release from cholinergic nerves in of established propranolol-induced bronchoconstriction. Frusemide did not demonstrate human airways in vitro. 35 This has led to the suggestion that propranolol may cause bron-any bronchodilator activity, in keeping with previous studies, 10 16 nor accelerate recovery of choconstriction by blockade of inhibitory presynaptic 2 adrenoceptors on cholinergic airway calibre following administration of salbutamol. The ability of frusemide to antagonise nerves. This mechanism is consistent with the absence of propranolol-induced broncho-propranolol-induced bronchoconstriction was weak compared with that of 2 agonists or constriction in normal subjects whose airways are less sensitive than those of asthmatic anticholinergic agents which are the agents of mones.
